Kiniksa Pharmaceuticals International (KNSA) net assets (shareholders' equity)

Net assets · fiscal 2025
$567.61M

Kiniksa Pharmaceuticals International (KNSA) had net assets of $567.61M at the end of fiscal 2025 (December 31, 2025). That is 29.5% higher than the $438.44M of fiscal 2024. Figures as of 19 Nov 2026, 11:36 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Net assets, fiscal 2025
$567.61M
Change on fiscal 2024
+29.5%
Growth, 5 years
+12.7% a year
Highest on record
$567.61Mfiscal 2025
Lowest on record
-$89.71Mfiscal 2017
Fiscal years on record
92017–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Kiniksa Pharmaceuticals International net assets (shareholders' equity), in more detail

Over the five fiscal years to 2025 net assets grew at a compound 12.7% a year. Across the 9 fiscal years on record (2017–2025), the highest was $567.61M in fiscal 2025 and the lowest -$89.71M in fiscal 2017.

History · 9 fiscal years

Net assets by fiscal year

Kiniksa Pharmaceuticals International net assets (shareholders' equity), year by year

Kiniksa Pharmaceuticals International (KNSA) net assets (shareholders' equity) by fiscal year
Fiscal yearNet assetsChangeYear ended
2025$567.61M 29.5% up
2024$438.44M 0.1% down
2023$438.84M 10.8% up
2022$396.15M 114.1% up
2021$185.04M 40.7% down
2020$311.94M 38.4% up
2019$225.42M 19.3% down
2018$279.27M—
2017-$89.71M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value.

How to read it

Large buybacks and write-offs shrink it without the business getting worse, so a falling or negative figure needs the reason before a verdict.

Net assets at health care companies of similar size

Net assets of Kiniksa Pharmaceuticals International and comparable companies
CompanyNet assetsFiscal year
Alkermes ALKS$1.82B2025
PACS Group PACS$946.77M2025
Kiniksa Pharmaceuticals International KNSA$567.61M2025
ImmunityBio IBRX-$500.47M2025
Cytokinetics CYTK-$659.63M2025
ABIVAX ABVX€455.21M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on KNSA

Kiniksa Pharmaceuticals International, figure by figure

Kiniksa Pharmaceuticals International (KNSA) overview: price, valuation and scorecardAll health care companies by market value

Kiniksa Pharmaceuticals International net assets (shareholders' equity): questions and answers

What are Kiniksa Pharmaceuticals International's net assets?

Kiniksa Pharmaceuticals International (KNSA) had net assets of $567.61M at the end of fiscal 2025 (December 31, 2025). That is 29.5% higher than the $438.44M of fiscal 2024.

What is the growth rate of Kiniksa Pharmaceuticals International's net assets?

Over the five fiscal years to 2025 net assets grew at a compound 12.7% a year.

What are the highest and lowest net assets figures on record for Kiniksa Pharmaceuticals International?

Across the 9 fiscal years on record (2017–2025), the highest was $567.61M in fiscal 2025 and the lowest -$89.71M in fiscal 2017.

How is Kiniksa Pharmaceuticals International's net assets calculated?

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value. For Kiniksa Pharmaceuticals International it is on record here for 9 fiscal years, 2017 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Kiniksa Pharmaceuticals International (KNSA) net assets (shareholders' equity)”, data as of 19 November 2026. https://funkfolio.com/stock/KNSA/net-assets

Underlying data: the company's filings with the SEC and Yahoo Finance.